CHICAGO — One-third of women oncologists surveyed reported experiencing infertility, according to study results presented at ASCO Annual Meeting.In addition, survey respondents reported feeling fertility preservation could have been helpful if it were available and affordable.
CHICAGO — Assessment of RUBY trial outcomes by blinded independent central review confirmed the benefits of adding dostarlimab to chemotherapy for women with primary advanced or recurrent endometrial cancer.The findings, presented at ASCO Annual Meeting, showed clinically meaningful PFS improvement with the dostarlimab (Jemperli, GSK) regimen vs. chemotherapy alone among women with mismatch
CHICAGO — Nearly one-fourth of academic oncologists surveyed reported feelings of burnout, with the highest rates among women and lesbian/gay/bisexual faculty, according to study results presented at ASCO Annual Meeting.The findings indicate an urgent need for tailored interventions at all levels to address factors driving burnout and its impact on attrition and career trajectory for
CHICAGO — One-year of adjuvant trastuzumab remains the standard-of-care treatment duration for most patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.However, certain patients with low/intermediate HER2-positive early breast cancer may benefit from a shorter, 9-week course of trastuzumab (Herceptin, Genentech), researchers noted.
CHICAGO — Adjuvant osimertinib conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA non-small cell lung cancer, according to results of the ADUARA trial presented at ASCO Annual Meeting.The findings, set to be published in The New England Journal of Medicine, provided further evidence that the addition of osimertinib (Tagrisso,